Sponsored by:
Facebook (FB)
Apple (AAPL)
JP Morgan (JPM)
Yahoo (YHOO)
Focus Stocks
Featured Stories
Ventas Declares Regular Quarterly Dividend of {loadposition newstories}.62 Per Share
Nucor To Acquire Skyline Steel LLC
Best ETFs For Facebook Exposure
Are the Bears Taking Control over F5 Networks?
Chico's FAS Reports First Quarter Earnings
New Ratings (ACHN, AMKR, BEAV, SGNT, TGI, VRA)
Published on Tuesday, 29 November 2011 08:14 Written by Danny Miller
New York, November 29th (TradersHuddle.com) – Following are some of the new analyst ratings before the market open.
Research Firms Initiate:
Achillion Pharmaceuticals (NASDAQ:ACHN) was initiated with Outperform and a target price of $9 at Wells Fargo.
Amkor Technology (NASDAQ:AMKR) was initiated with a Hold and a target price of $4 at Deutsche Bank.
BE Aerospace (NASDAQ:BEAV), the maker of interior products for commercial, military, and general aviation aircraft cabins, was initiated with a Buy and a target price of $49 at Sterne Agee.
Sagent Pharmaceuticals (NASDAQ:SGNT) was initiated with a Buy and a target price of $25 at Collins Stewart.
Triumph Group (NYSE:TGI) was initiated with a Buy and a target price of $71 at Sterne Agee.
Vera Bradley (NYSE:VRA) was initiated with a Neutral at JP Morgan.
Related Articles
- Achillion Announces Additional Proof-of-Concept Data With ACH-2684 for the Treatment of Hepatitis C
- Amkor Technology Announces Plans to Build State-of-the-Art Factory and Global R&D Center in Korea
- Sagent Pharmaceuticals Announces Launch of Atracurium Besylate Injection, USP
- Achillion Announces Executive Promotion
- Sagent Pharmaceuticals Announces Launch of Irinotecan Hydrochloride Injection in Single Dose Vials
- Sagent Pharmaceuticals Reports First Quarter 2012 Financial Results
- Achillion Reports First Quarter 2012 Financial Results
- Achillion Advances Second Generation Pan-Genotypic NS5A Inhibitor, ACH-3102, Into Clinical Development
- Up/Downgrades
- Triumph Group Reports Record Fourth Quarter and Full Fiscal Year 2012 Results
Related Partner Headlines
- Sagent Pharmaceuticals Announces Launch of Irinotecan Hydrochloride Injection in Single Dose Vials - Benzinga
- Top 4 NASDAQ Stocks In The Semiconductor-Integrated Circuits Industry With The Highest Revenue - Benzinga
- ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C - Benzinga
- UPDATE: Morgan Stanley Cuts PT to $27 on Sagent Pharmaceuticals; Progress Amid Soft Q1 - Benzinga
- BE Aerospace Inc (BEAV): Today's Featured Aerospace/Defense Winner - TheStreet.com
- UPDATE: UBS Investment Research Upgrades Achillion to Neutral; Balanced Risk/Reward - Benzinga
- 5 Short Squeeze Candidates in the Technology Sector - Benzinga
- Achillion Stock Gaps Down On Today's Open (ACHN) - TheStreet.com
- BE Stock Hits New 52-Week High (BEAV) - TheStreet.com
- For Biotech, 'Fail' is Making a Big Comeback - TheStreet.com
Volatile market? That's when profit potential skyrockets for options traders. Now you can get up to 50 trade opportunities a week from top options experts -- plus much more -- on our exciting new site OptionsProfits.
Try it FREE!
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
Stock Market
Loading
